Starting July 1, Medicare will cover GLP-1 weight-loss drugs at a $50/month cap for qualifying beneficiaries, marking the first time older Americans gain access to this coverage. The policy shift expands the addressable market meaningfully for Eli Lilly and positions rival Amgen's oral obesity candidate as a potential beneficiary if coverage extends further.

NVIDIA unveiled the Vera Rubin platform, its next-generation GPU/CPU architecture succeeding Blackwell, at GTC 2025. The announcement extends NVIDIA's AI roadmap visibility but arrives as the stock already trades on lofty expectations baked into $215.9B revenue guidance and 71% gross margins.

Vicor Corporation is gaining attention as a high-stakes AI power conversion play, with revenue up 26.1% YoY to $452.7M and healthy 57.3% gross margins. The framing as an 'AI bet' raises the question of whether VICR's valuation already prices the AI tailwind or whether accelerating data-center power demand offers a genuine re-rating catalyst.

Nvidia and Alphabet are lagging a broader megacap tech bounce as chip stocks face renewed selling pressure, diverging from peers like Microsoft and Meta. The underperformance raises the question of whether this is a tactical dip in two fundamentally strong names or the start of a more sustained rotation out of AI-adjacent leaders.